V itamin D plays a role in the regulation of hundreds of genes involved in bone and mineral metabolism, the renin-angiotensin-aldosterone system, the immunologic system, the cardiovascular system, muscle metabolism and strength, cellular proliferation and differentiation, and survival of cells in disorders such as cancer (1-3). Recognition of the important role of vitamin D in health and disease has created the incentive to optimize vitamin D status in people. Adequate status is currently defined by total concentrations of serum 25-hydroxyvitamin vitamin
D (25(OH)D)
because this metabolite is hydroxylated to biologically active 1␣,25-dihydroxyvitamin D (1,25(OH 2 )D). Only small fractions of circulating 1,25(OH) 2 D and 25(OH)D are in the unbound, or free, state. Nonetheless, the free-hormone hypothesis attributes biologic activity of hormones to the unbound or free fractions rather than protein bound concentrations in the circulation.
The potential benefit of measuring free or unbound concentrations of 25(OH)D and its metabolites has been suggested and is being evaluated (7) (8) (9) (10) . Until recently, determinations of serum free 25(OH)D involved laborious forms of equilibrium dialysis or indirect estimation based on measurement of vitamin D binding protein (DBP), albumin, and 25(OH)D (using 25(OH)D standards and assays that were variable) with equations derived from relatively small numbers of people (7) or modified from equations used for sex hormones (11) . An assay that directly measures serum free 25(OH)D levels has been developed (Future Diagnostics BV). Our primary goal was to compare directly measured circulating free 25(OH)D concentrations with calculated free 25(OH)D levels in humans with and without conditions associated with alterations in albumin and DBPs. A secondary goal was to compare relationships between directly measured and calculated free 25(OH)D concentrations with a biomarker of vitamin D effect.
Subjects and Methods

Subjects
Stable subjects with cirrhosis and evidence of protein synthetic dysfunction defined as an albumin concentration Ͻ2.9 g/dL, women in their second and third trimester of pregnancy, and medically stable community-dwelling adults without evidence of liver disease or pregnancy provided informed consent and venous blood samples as part of research protocols approved by the University of California, San Francisco, Committee on Human Research.
Laboratory measurements
Total 25(OH)D measurements were determined by Clinical Laboratory Improvement Amendments-certified liquid chromatography tandem mass spectrometry at Mayo Clinical Laboratories, Rochester, Minnesota, with participation in National Institutes of Health Office of Dietary Supplements-funded National Institute of Standards and Technology (NIST) quality assurance program for analysis of 25(OH)D metabolites in human serum. The assay has ϳ10% coefficient of variation (CV) at levels Ն10 ng/mL. Internal standard is the NIST reference standard.
Albumin was measured at Heartland Assays, Inc by Bromcresol green (BCG) dye-binding procedure (albumin reagent set from Pointe Scientific, Inc).
Vitamin D binding protein was measured using the Quantikine Human Vitamin D Binding Protein Immunoassay kit (Catalog number DDBP0, R&D Systems, Inc) at Heartland Assays, Inc.
Free 25(OH)D levels
Calculated free 25(OH)D was determined using the method reported by Bikle et al (7) and by modification of the Vermuelen method for free testosterone estimation (11) . The equations and affinity constants used in these calculations are provided in the Supplemental Appendix (published on The Endocrine Society's Journals Online website at http://jcem.endojournals.org). Direct measurement of free 25(OH)D concentrations was made by immunoassay (Future Diagnostics BV; http://www.futurediagnostics.nl/) In this assay, an anti-vitamin D antibody is coated on a microtiter plate. Serum samples and calibrators are pipetted into the wells of the microtiter plate. Free 25(OH)D is captured by the antibody during a first incubation. After washing, a biotin-labeled 25(OH)D analog is allowed to react with the unoccupied antibody binding sites in a second incubation. After a second washing step and incubation with a streptavidin-peroxidase conjugate, bound enzyme is quantitated using a colorimetric reaction. Intensity of the signal is inversely proportional to the level of free 25(OH)D in the sample. The assay was calibrated against a symmetric dialysis method. The calibrator range was 0.0 to 35.0 pg/mL. The limit of blank and limit of detection of the assay were determined according to the Clinical Laboratories and Standards Institute (CLSI) guideline EP17-A (12). The limit of blank from 60 replicates was 0.7 pg/mL. The limit of detection was determined from the pooled SD from 12 measurements of 5 low samples. The limit of detection was 1.9 pg/mL. Imprecision was determined on 3 samples during 20 consecutive days with 2 runs per day according to the CLSI EP05-A2 guidelines (13) . At 23.6 pg/mL, the CV was 3% between runs and 1.1% between days with total imprecision CV of 5.6%; at 13.2 pg/mL, the between-run CV was 4.3% and between-day CV was 1% with a total imprecision CV of 6.9%. At 5.02 pg/mL, the between-run CV was 6.2% and between-day CV was 4.5% with a total imprecision CV of 15.7%. The antibody in this assay detects 25(OH)D 2 at a level that is 60% that of 25(OH)D 3 .
Intact PTH (iPTH) was measured at San Francisco General Hospital Clinical Laboratories using the Siemens ADVIA Centaur assay, a 2-site sandwich immunoassay using direct chemiluminometric technology.
Statistical design and data analysis
Demographic and clinical characteristics and assay results of groups are presented as mean Ϯ SD and compared using ANOVA. Linear regression was used to test for relationships between directly measured and calculated free 25(OH)D concentrations, between free 25(OH)D and total 25(OH)D, and between free 25(OH)D measurements and iPTH. Data were transformed before analysis if nonnormally distributed. Post hoc tests of fold change differences using different equilibrium association constants (ka) for DBP were made by unpaired t test, and 25(OH)D 2 presence and dose effects on errors in fold change were tested by 2 .
Results
Participants
A total of 151 subjects participated. Demographic characteristics by group (cirrhotic, pregnant, and compar-ator group) and mean values for estimated glomerular filtration rate, albumin, calcium, DBP, 25(OH)D measurements, and iPTH are presented in Table 1 . Patients with cirrhosis had a mean Model for End-Stage Liver Disease (MELD) score of 16 Ϯ 3 with Child Pugh score B in onethird and C in two-thirds (14, 15) . Half of the pregnant women were in the second trimester of pregnancy, and half were in the third. The comparison group of 107 included 28 healthy normal subjects under the age of 50 years and 79 medically stable adults. Of the 79 medically stable adults, 58 did not have diabetes, heart failure, liver disease, renal disease, or pregnancy; 56 had hypertension and 15 had diabetes. No sex hormones were taken by any of the women or men.
Laboratory measures
Total 25(OH)D, DBP, and albumin were lowest in patients with cirrhosis, but measured free 25(OH)D was highest in this group (P Ͻ .001, Table 1 and Figure 1 ). DBP was highest in pregnant women (P Ͻ .001), resulting in the lowest calculated free 25(OH)D, but measured free 25(OH)D did not differ from the entire comparison group (Table 1) or from nonpregnant, noncirrhotic women not taking estrogen or progesterone (4 Ϯ 1.1 vs 3.5 Ϯ 2.0 pg/mL, respectively). Total 25(OH)D levels also did not differ between the pregnant and comparison group.
Race significantly affected DBP levels (P Ͻ .03), with African Americans having the lowest levels (152 Ϯ 107 g/mL), followed by Asians (166 Ϯ 83 g/mL), and with Caucasians having the highest (301 Ϯ 210 g/mL). Excluding data from the cirrhotic and pregnancy groups, DBP remained highest in Caucasians and lowest in African Americans (259 Ϯ 91 compared with 121 Ϯ 71 g/mL, P Ͻ .01) Despite DBP differences, directly measured free 25(OH)D was not affected by race when all subjects were considered (P ϭ .15) or after exclusion of data from the cirrhotic subjects or pregnant women (3.6 Ϯ 1.8 vs 3.5 Ϯ 1.3 pg/mL in Caucasians vs African Americans, respectively, P ϭ .7)
Calculated and measured free 25(OH)D
Calculations using a method described by Bikle et al (7) or one modified from the Vermuelen method (11) produced almost identical estimates (y ϭ Ϫ0.13 ϩ 1.031x; r 2 Table 1 ). Therefore, further results will be presented for the simpler Bikle method (7). 
Relationships with DBP
Directly measured free 25(OH)D was not correlated with DBP for the entire sample or within subgroups (P ϭ .35-.76). Calculated free 25(OH)D was highly inversely correlated with DBP (P Ͻ .0001, r 2 ϭ 0.36) as expected because the calculations include DBP.
Relationships with iPTH
Significant inverse relationships were detected between iPTH and measured free 25(OH)D (iPTH ϭ 83.4 -16.7 ϫ ln free 25(OH)D; r 2 ϭ 0.036, P Ͻ .02) but not between iPTH and calculated free 25(OH)D (P ϭ .46, r 2 ϭ0.006). Similarly, measured free 25(OH)D but not calculated free 25(OH)D was correlated with calcium concentrations (r 2 ϭ 0.035, P Ͻ .004; and r 2 ϭ 0.004, P ϭ .47, respectively). As expected, total 25(OH)D concentrations were also inversely correlated with iPTH (iPTH ϭ 100.4 -12.74 ϫ ln total 25(OH)D; r 2 ϭ 0.023, P Ͻ .05) and positively related to calcium concentrations (r 2 ϭ 0.021, P Ͻ .08).
Discussion
The free hormone hypothesis postulates that proteinbound ligands cannot freely cross the cell membrane to interact with cytoplasmic or nuclear binding proteins, whereas unbound free small lipophilic ligands can cross cell membranes and access cytoplasmic or nuclear bound proteins to exert effects. A large amount of biochemical, cellular, and physiologic data strongly support the free The major binding and transport protein for vitamin D and its metabolites is DBP, which binds 85% of 25(OH)D. Albumin and lipoproteins account for another 15% due to a much lower affinity despite their much higher serum concentrations. Variation in DBP levels and binding properties have been reported in humans (7, 8, 16 -19) . Diseases such as cirrhosis result in decreased protein synthetic capacity and lower DBP concentrations that increase the percent free 25(OH)D concentrations resulting in free concentrations that are similar to those seen in normal subjects despite lower total 25(OH)D concentrations (7) . DBP has also been reported to be lower in African Americans compared with Caucasians, and this could result in normal free 25(OH)D levels despite lower total 25(OH)D concentrations (20) . Conversely, circulating DBP is increased during pregnancy, especially during the second and third trimesters, and would be expected to result in decreased percentages of free 25(OH)D concentrations.
Phenotypic variations in DBP based on isoelectric focusing migration have been recognized with more recent descriptions of polymorphisms in the DBP gene that alter the binding affinity for vitamin D ligands (21) (22) (23) . Three alleles, group-specific component (Gc) 1F, 1S, and 2 have been observed in all human groups studied. However, the prevalence of alleles show distinct racial distribution patterns with African American and Asian populations more likely to carry the higher-affinity (Gc1F; CAT haplotype) form of DBP, whereas Caucasians more frequently have the lower-affinity DBP genotypes (Gc1S and Gc2) (24, 25) . The relative difference of affinity constants of Gc1F and Gc1s in humans is about 2-fold (22) . Unfortunately, current equations for calculation of free 25(OH)D assume 1 DBP binding affinity constant (7 ϫ 10 8 M Ϫ1 ).
Directly measured free 25(OH)D was highest in patients with cirrhosis when compared with either pregnant women or the comparator group despite lower total 25(OH)D. In contrast to expectations, free 25(OH)D concentrations did not differ in pregnant women vs the comparator group, even when sex-matched and with exclusion of women on sex hormones in the comparator group. These results are consistent with the observation made by Bikle et al (26) that affinity of DBP for the vitamin D metabolites appears to be decreased during pregnancy, perhaps compensating for increased DBP concentrations to maintain the free metabolite levels. Whether this reflects the influence of changes in the hormonal milieu during pregnancy on DBP affinity is not known. The other unexpected finding was that free 25(OH)D levels were not affected by race, despite lower DBP levels in African Americans. The lower DBP levels may explain the lower total 25(OH)D levels generally found in African Americans and contribute to a higher free concentration than would be expected even with the greater prevalence of high-affinity DBP forms found in African Americans.
Our primary goal was to compare directly measured circulating free 25(OH)D concentrations with calculated free 25(OH)D levels. A direct positive statistically significant correlation was found that accounted for only 13% of the variation. In general, the calculations overestimated the directly measured free 25(OH)D concentration. The differences were most pronounced with mean 3-fold differences in African Americans compared with 1.5-fold differences in Caucasians. The equations to estimate free 25(OH)D rely heavily on DBP concentrations with a single assumed affinity constant. As a post hoc analysis, we recalculated free 25(OH)D levels assuming a 1.9-fold higher DBP affinity constant for 25(OH)D in African Americans compared with Caucasians based on relative Gc frequencies and equilibrium association constant (ka) differences (24, 25, 27) . This reduced the mean overestimation in African Americans to 1.6 Ϯ 1.2-fold, which did not differ from that in Caucasians (1.5 Ϯ 0.6-fold), supporting the premise that differences in DBP binding affinity may have been responsible for the overestimation differences between the races. Nonetheless, there remained a considerable 1. 
